

Erasmus University Rotterdam, the Netherlands
CSC PhD 2015 Project Description

School/Department:	<i>Department of Urology</i>
Project Title:	<i>Screening for prostate cancer: differences in outcome in Europe and China</i>
Abstract:	<p>Since 1993 a European randomized controlled trial studying the effect of PSA based screening on prostate cancer specific mortality is ongoing (www.erspc.org). The Dutch center (Erasmus University, department of Urology) is involved with a total of 42,000 participants. In addition to studies relating to the screening tests/algorithm, detailed follow-up on tumor characteristics, treatment and outcome are recorded of all men diagnosed with prostate cancer, in both screening and control arm.</p> <p>A PhD student can participate in analyses regarding treatment outcome and will be involved in assessing tumor volumes in those men treated with radical prostatectomy. In addition he/she can participate in comparative analyses of prostate cancer screening in Europe and China together with our partner Prof. Gang Zhu from Beijing Hospital of Ministry of Health, China. All together this work can form a solid basis for a PhD degree.</p>
Requirements of candidate:	<p>Master degree: Yes</p> <p>Urology and in addition some epidemiological knowledge on prostate cancer (screening) and preferably acquainted with statistical packages like SPSS</p> <p>IELTS Grade: 7.0 (<i>minimal 6.0 per component</i>) or TOEFL: 100 (<i>minimal 20 per component</i>)</p>
Supervisor information:	<p>Monique J. Roobol, Ph.D. Associate Professor Department of Urology Erasmus MC Room Na-1706 P.O. Box 2040 3000 CA Rotterdam The Netherlands phone: +31-10-703 2240</p>

	<p>m.roobol@erasmusmc.nl</p> <p>http://scholar.google.nl/citations?user=XJXGqQsAAAAJ&hl=en</p> <p>Dr. Monique J. Roobol is associate professor and the head of the screening office of the Department of Urology at Erasmus Medical Centre Rotterdam, The Netherlands. She has a master and PhD degree in epidemiology. In the past she worked as a research technician in molecular biology.</p> <p>The screening office of the Department of Urology performs several clinical and population based screening studies. On average three to four PhD students are working under her guidance. She is responsible for the Dutch part of the European Randomized study of Screening for prostate cancer (www.erspc.org), the prostate cancer active surveillance project PRIAS (www.prias-project.org) and the Movember Global Action Plan-3 (active surveillance). She is a board member of the ERSPC study group, the ERSPC Foundation and the Dutch Prostate Cancer research Foundation (SWOP). Next to this she is an active member of the Epidemiology committee of the ERSPC. Her main interest is in predictive modeling (www.prostatecancer-riskcalculator.com) .</p> <p>recent publication list:</p> <p>1: Roobol MJ, Bokhorst LP. <i>The ProtecT trial: what can we expect?</i> <i>Lancet Oncol.</i> 2014 Sep;15(10):1046-7. doi: 10.1016/S1470-2045(14)70198-6. Epub 2014 Aug 19. PMID: 25163904.</p> <p>2: Venderbos LD, van den Bergh RC, Roobol MJ, Schröder FH, Essink-Bot ML, Bangma CH, Steyerberg EW, Korfage IJ. <i>A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.</i> <i>Psychooncology.</i> 2014 Aug 20. PMID: 25138075.</p> <p>3: Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A;for the ERSPC Investigators. <i>Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13years of follow-up.</i> <i>Lancet.</i> 2014 Aug 6. PMID: 25108889.</p> <p>4: Roobol MJ. <i>Prostate cancer: Rescreening policies and risk calculators.</i> <i>Nat Rev Urol.</i> 2014 Aug;11(8):429-30.PMID: 24980199.</p>
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- 5: Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. *J Natl Cancer Inst.* 2014 Apr 26;106(5). PMID: 24771874.
- 6: Roobol MJ. International perspectives on screening. *Urol Clin North Am.* 2014 May;41(2):237-47 PMID: 24725486.
- 7: Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, Wolters T, Barentsz JO, Roobol MJ. Prostate cancer antigen 3:diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥ 100 . *Urology.* 2014 Mar;83(3):613-6. PMID: 24581524.
- 8: Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wiklund P. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. *BMJ.* 2014 Feb 26;348:g1502. PMCID: PMC3936107.
- 9: Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. *BMC Med.* 2014 Feb 11;12:26. PMCID: PMC3922189.
- 10: Roobol MJ, Schröder FH. The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message? *Eur Urol.* 2014 Jun;65(6):1056-7. PMID: 24486022.
- 11: Sooriakumaran P, Wiklund P, Roobol MJ, Steyerberg E, Sanchez-Salas R, Cathelineau X, Tewari AK. Reply to Gianluca Giannarini, Nazareno Suardi and Alberto Briganti's letter to the editor re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22 393 open, laparoscopic, and robot-assisted radical prostatectomy patients. *Eur Urol.* In press. . *Eur Urol.* 2014 Jun;65(6):e91-2. PMID: 24447573.
- 12: Zappa M, Puliti D, Hugosson J, Schröder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Borda AP, Roobol MJ, Villers A. A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. *Eur Urol.* 2014 Jan 7. pii: S0302-2838(13)01480-2. PubMed PMID: 24412230.
- 13: Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ. Validation of stem cell markers in clinical prostate cancer: $\alpha 6$ -integrin is predictive for non-aggressive disease. *Prostate.* 2014 May;74(5):488-96.

- 14: Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Motttrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AK. A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. *Eur Urol*. 2013 Nov 24 PMID: 24290695.
- 15: Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambroek T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk re-stratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study. *Invest Radiol*. 2014 Mar;49(3):165-72. PMID: 24220253.
- 16: Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. *Eur Urol*. 2014 Feb;65(2):329-36. PMID: 23954085.
- 17: Roobol MJ. The prostate-specific antigen test. *Expert Opin Med Diagn*. 2013 Sep;7(5):423-6. PMID: 23875974.
- 18: de Bekker-Grob EW, Bliemer MC, Donkers B, Essink-Bot ML, Korfage IJ, Roobol MJ, Bangma CH, Steyerberg EW. Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment. *Br J Cancer*. 2013 Aug 6;109(3):633-40 PMID: 23860533;